News

Thallion Pharmaceuticals (Thallion) has signed a binding Letter of Intent (LOI) with LFB Biotechnologies (LFB) for the development of Shigamabs, Thallion’s product candidate for the treatment of Shiga

PolyMedix has completed the first two segments of a phase 1B clinical safety study with its antibiotic drug candidate, PMX-30063. PMX-30063 is small-molecule mimetic of host defense proteins

Ista has submitted a supplemental New Drug Application (sNDA) to the FDA for bromfenac ophthalmic solution as a treatment for ocular inflammation and pain following cataract surgery. Ista

Amgen has received a positive opinion for the marketing authorisation of Prolia (denosumab) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency

Boehringer Ingelheim and Pfizer have received FDA approval for Spiriva HandiHaler (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

McNeil Consumer Healthcare (McNeil), division of McNEIL-PPC, has been expanding its voluntary recall to include all available product lots of Tylenol arthritis pain caplet 100 count bottles, with

The United States Patent and Trademark Office (USPTO) has determined that US Patent No. 6444673, which is a composition of matter patent that covers Sepracor’s human drug product,

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to GlaxoSmithKline (GSK) for Revolade (Eltrombopag). The drug is aimed for

Ambit Biosciences (Ambit) and Astellas Pharma (Astellas) have entered into a worldwide agreement to jointly develop and commercialise FLT3 kinase inhibitors in oncology and non-oncology indications. The partnership